rabeprazole has been researched along with Obesity in 4 studies
Rabeprazole: A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Overweight/obesity in GORD patients does not appear to affect the antisecretory efficacy of a single dose of rabeprazole and pantoprazole." | 5.17 | On-demand proton pump inhibitory treatment in overweight/obese patients with gastroesophageal reflux disease: are there pharmacodynamic arguments for using higher doses? ( Bruley des Varannes, S; Coudsy, B; Delemos, B; Ducrotté, P; Lococo, J; Waechter, S; Xiang, J, 2013) |
| "To investigate whether overweight/obesity (BMI≥25 kg/m(2)) affects rabeprazole clinical efficacy versus omeprazole in patients with erosive esophagitis (EE)." | 5.15 | Does BMI affect the clinical efficacy of proton pump inhibitor therapy in GERD? The case for rabeprazole. ( Casalini, S; Coudsy, B; DeLemos, B; Li, H; LoCoco, J; Pace, F; Pelosini, I; Scarpignato, C; Sun, Y; Xiang, J, 2011) |
| "Obesity is associated with a risk of gastroesophageal reflux disease." | 2.79 | Controlling on-demand gastric acidity in obese subjects: a randomized, controlled trial comparing a single dose of 20 mg rabeprazole and 20 mg omeprazole. ( Belhocine, K; Bruley des Varannes, S; Flet, L; Touchefeu, Y; Vavasseur, F; Volteau, C, 2014) |
| "It is suggested that nonalcoholic fatty liver disease (NAFLD), including nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH), can be associated with insomnia and gastro-esophageal reflux disease (GERD)." | 1.40 | The association of insomnia with gastroesophageal reflux symptoms in biopsy-proven nonalcoholic fatty liver disease. ( Chayama, K; Eguchi, Y; Fujii, H; Fujimoto, K; Hyogo, H; Imajo, K; Itoh, Y; Kanemasa, K; Nakajima, A; Ono, M; Saibara, T; Sumida, Y; Taketani, H; Tanaka, S; Yoneda, M; Yoshikawa, T, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bruley des Varannes, S | 2 |
| Coudsy, B | 2 |
| Waechter, S | 1 |
| Delemos, B | 2 |
| Xiang, J | 2 |
| Lococo, J | 2 |
| Ducrotté, P | 1 |
| Taketani, H | 1 |
| Sumida, Y | 1 |
| Tanaka, S | 1 |
| Imajo, K | 1 |
| Yoneda, M | 1 |
| Hyogo, H | 1 |
| Ono, M | 1 |
| Fujii, H | 1 |
| Eguchi, Y | 1 |
| Kanemasa, K | 1 |
| Chayama, K | 1 |
| Itoh, Y | 1 |
| Yoshikawa, T | 1 |
| Saibara, T | 1 |
| Fujimoto, K | 1 |
| Nakajima, A | 1 |
| Belhocine, K | 1 |
| Vavasseur, F | 1 |
| Volteau, C | 1 |
| Flet, L | 1 |
| Touchefeu, Y | 1 |
| Pace, F | 1 |
| Sun, Y | 1 |
| Casalini, S | 1 |
| Li, H | 1 |
| Pelosini, I | 1 |
| Scarpignato, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT01136317] | Phase 2 | 0 participants | Interventional | 2010-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for rabeprazole and Obesity
| Article | Year |
|---|---|
On-demand proton pump inhibitory treatment in overweight/obese patients with gastroesophageal reflux disease: are there pharmacodynamic arguments for using higher doses?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Cross-Over Studies; Double-Blind M | 2013 |
Controlling on-demand gastric acidity in obese subjects: a randomized, controlled trial comparing a single dose of 20 mg rabeprazole and 20 mg omeprazole.
Topics: Adult; Double-Blind Method; Female; Gastric Acid; Gastric Acidity Determination; Humans; Hydrogen-Io | 2014 |
Does BMI affect the clinical efficacy of proton pump inhibitor therapy in GERD? The case for rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Body Mass Index; Double-Blind Method; Esophagitis, P | 2011 |
1 other study available for rabeprazole and Obesity
| Article | Year |
|---|---|
The association of insomnia with gastroesophageal reflux symptoms in biopsy-proven nonalcoholic fatty liver disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biopsy; Female; Gastroesophageal Reflux; Humans; Japan; | 2014 |